Esperion Therapeutics, Inc.
ESPRNASDAQHealthcare● Active
$3.15
+$0.02(+0.64%)
Market Cap$654912465
P/E Ratio—
52W High$4.18
52W Low$0.95
Esperion Therapeutics, Inc. (ESPR) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ESPR · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.02B) | ($0.05B) | ($0.21B) | ($0.23B) | ($0.27B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.01B | $0.02B | $0.02B |
| Change in Working Capital | ($0.01B) | ($0.06B) | $0.01B | ($0.00B) | ($0.05B) |
| Net Cash from Operations | ($0.01B) | ($0.02B) | ($0.14B) | ($0.17B) | ($0.26B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | ($0.06B) | ($0.05B) |
| Sales of Investments | $0.00B | $0.00B | $0.04B | $0.07B | $0.00B |
| Net Cash from Investing | $0.00B | ($0.00B) | $0.04B | $0.01B | ($0.05B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.05B) | $0.04B | $0.00B | $0.00B | ($0.00B) |
| Net Cash from Financing | $0.04B | $0.09B | $0.05B | $0.03B | $0.27B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.01B) | ($0.02B) | ($0.14B) | ($0.17B) | ($0.26B) |
| FCF Margin %(computed) | -3.25% | -7.21% | -116.46% | -231.64% | -336.29% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Esperion Therapeutics, Inc. data
About Esperion Therapeutics, Inc. (ESPR) Cash Flow Statement
Esperion Therapeutics, Inc. generated operating cash flow of ($0.01B) and free cash flow of ($0.01B) for 2025 — a FCF margin of -3.25%. Capital expenditure was $0.00B.
Frequently asked questions
ESPR · 4 questionsEsperion Therapeutics, Inc. generated free cash flow of ($0.01B) for 2025, up 45.4% year-over-year.
ESPR free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10